[{"address1": "1901 West 47th Place", "city": "Kansas City", "state": "KS", "zip": "66205", "country": "United States", "phone": "913 942 2300", "website": "https://www.cingulate.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Dr. Shane J. Schaffer Pharm.D., PharmD", "age": 47, "title": "CEO, Principal Financial Officer & Chairman of the Board", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 491961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Laurie A. Myers M.B.A., Ph.D.", "age": 65, "title": "Executive VP & COO", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 415167, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew N. Brams M.D.", "age": 58, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 244792, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer L. Callahan CPA", "age": 52, "title": "CFO, Senior VP & Corporate Controller", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raul R. Silva M.D.", "age": 64, "title": "Executive VP & Chief Science Officer", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Thomas  Dalton", "title": "Head of Investor & Public Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.07, "open": 1.05, "dayLow": 0.96, "dayHigh": 1.06, "regularMarketPreviousClose": 1.07, "regularMarketOpen": 1.05, "regularMarketDayLow": 0.96, "regularMarketDayHigh": 1.06, "beta": -0.931, "forwardPE": 1.3205129, "volume": 126225, "regularMarketVolume": 126225, "averageVolume": 337819, "averageVolume10days": 216170, "averageDailyVolume10Day": 216170, "bid": 0.9951, "ask": 1.07, "bidSize": 100, "askSize": 100, "marketCap": 5160784, "fiftyTwoWeekLow": 0.96, "fiftyTwoWeekHigh": 23.8, "fiftyDayAverage": 1.4228, "twoHundredDayAverage": 8.117645, "currency": "USD", "enterpriseValue": 2639165, "floatShares": 915243, "sharesOutstanding": 4839470, "sharesShort": 42716, "sharesShortPriorMonth": 113330, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0088, "heldPercentInsiders": 0.083529994, "heldPercentInstitutions": 0.101160005, "shortRatio": 0.16, "shortPercentOfFloat": 0.0094, "impliedSharesOutstanding": 5010470, "bookValue": -0.111, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -21205276, "trailingEps": -31.2, "forwardEps": 0.78, "lastSplitFactor": "1:20", "lastSplitDate": 1701302400, "enterpriseToEbitda": -0.132, "52WeekChange": -0.9485, "SandP52WeekChange": 0.26653707, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CING", "underlyingSymbol": "CING", "shortName": "Cingulate Inc.", "longName": "Cingulate Inc.", "firstTradeDateEpochUtc": 1638973800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bf898f9d-c1c1-3f31-9c96-a5b2c0f73dcd", "messageBoardId": "finmb_1674914781", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.03, "targetHighPrice": 35.0, "targetLowPrice": 8.0, "targetMeanPrice": 21.5, "targetMedianPrice": 21.5, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 1986313, "totalCashPerShare": 2.12, "ebitda": -19936746, "totalDebt": 3604148, "quickRatio": 0.354, "currentRatio": 0.506, "returnOnAssets": -1.20235, "returnOnEquity": -5.12812, "freeCashflow": -9646880, "operatingCashflow": -16678666, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-07"}]